Business
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025 --In preclinical studies, REX-8756 elicited complete, rapid and durable inhibition of STAT6, resulting in potent, biologic-like activity without protein degradation in models of inflammatory diseases --Several healthy volunteers have already received REX-8756, triggering a milestone payment of $20 million to Recludix under the collaboration with Sanofi SAN DIEGO
About this update from Sanofi Sa
[{"type":"image","alt":"Recludix Pharma, Inc.","displaySize":"","headline":null,"caption":"Recludix Pharma, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":116,"url":"https://media.zenfs.com/en/globenewswire.com/026898f85cb6a19f92dd37096effd527"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/LT.K7PPcvw4cLaZ9aUGNvg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE2MjtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/026898f85cb6a19f92dd37096effd527","width":300,"height":116}},"lazy":false},{"type":"text","content":"--Phase 1 study of REX-8756 is well underway following FDA clearance of the Investigational New Drug (IND) application in December 2025","length":135,"tagName":"p"},{"type":"text","content":"--In preclinical studies, REX-8756 elicited complete, rapid and durable inhibition of STAT6, resulting in potent, biologic-like activity without protein degradation in models of inflammatory diseases","length":199,"tagName":"p"},{"type":"text","content":"--Several healthy volunteers have already received REX-8756, triggering a milestone payment of $20 million to Recludix under the collaboration with Sanofi","length":154,"tagName":"p"},{"type":"text","content":"SAN DIEGO, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Recludix Pharma, a clinical-stage company leading the discovery and development of inhibitors of challenging targets for inflammatory disease, today announced it has begun dosing healthy volunteers in a Phase 1 study of REX-8756 (also known as SAR448755), an oral, small molecule STAT6 inhibitor that has demonstrated compelling efficacy and safety in preclinical models of different types of inflammatory diseases based on selective and complete STAT6 inhibition. The achievement of this milestone triggered a payment of $20 million to Recludix under the collaboration agreement with Sanofi.","length":637,"tagName":"p"},{"type":"text","content":"“The initiation of our first clinical study is a pivotal step forward in executing our long-term vision of discovering and developing innovative medicines for patients in need. This milestone reflects the strength of our science and platform, as well as the capabilities of our highly experienced team,” said Nancy Whiting, Pharm.D., president and chief executive officer of Recludix. “We see tremendous potential for our STAT6 inhibitor, REX-8756, to set a new standard in the treatment...